Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies

Sponsor
Sanofi (Industry)
Overall Status
Terminated
CT.gov ID
NCT03367819
Collaborator
(none)
44
16
6
38.1
2.8
0.1

Study Details

Study Description

Brief Summary

Primary Objectives:
  • To characterize the safety and tolerability of isatuximab in combination with REGN2810 in participants with metastatic, castration-resistant prostate cancer (mCRPC) who were naïve to anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1)-containing therapy, or non-small cell lung cancer (NSCLC) who progressed on anti-PD-1/PD-L1-containing therapy, and to confirm the recommended Phase 2 dose (RP2D).

  • To assess the response rate of isatuximab in combination with REGN2810 in participants with either mCRPC who were anti-PD-1/PD-L1 therapy naive, or NSCLC who progressed on anti-PD-1/PD-L1 therapy, or of isatuximab as single agent in participants with mCRPC.

Secondary Objectives:
  • To evaluate the safety of the combination of isatuximab with REGN2810 or isatuximab monotherapy.

  • To evaluate the immunogenicity of isatuximab and REGN2810.

  • To characterize the pharmacokinetic (PK) profile of isatuximab single agent or in combination with REGN2810, and to characterize the PK of REGN2810 in combination with isatuximab.

  • To assess overall efficacy of isatuximab in combination with REGN2810 or as a single agent.

Condition or Disease Intervention/Treatment Phase
  • Drug: Isatuximab SAR650984
  • Drug: Cemiplimab REGN2810
Phase 1/Phase 2

Detailed Description

The total study duration per participant was up to 28 months including an up to 28 days screening period, an up to 24 months treatment period, and a 3 months safety follow up period.

Study Design

Study Type:
Interventional
Actual Enrollment :
44 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Random assignment used only for allocation to Cohort A-1 or A-2Random assignment used only for allocation to Cohort A-1 or A-2
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With REGN2810, or Isatuximab Alone, in Patients With Advanced Malignancies
Actual Study Start Date :
Jan 4, 2018
Actual Primary Completion Date :
Mar 10, 2021
Actual Study Completion Date :
Mar 10, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Phase 1: mCRPC/NSCLC

Isatuximab dose 1 and REGN2810 predefined dose

Drug: Isatuximab SAR650984
Pharmaceutical form: solution for infusion Route of administration: intravenous
Other Names:
  • Sarclisa
  • Drug: Cemiplimab REGN2810
    Pharmaceutical form: solution for infusion Route of administration: intravenous

    Experimental: Cohort A-1: mCRPC, isatuximab and REGN2810 combination

    Participants with mCRPC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose

    Drug: Isatuximab SAR650984
    Pharmaceutical form: solution for infusion Route of administration: intravenous
    Other Names:
  • Sarclisa
  • Drug: Cemiplimab REGN2810
    Pharmaceutical form: solution for infusion Route of administration: intravenous

    Experimental: Cohort A-2: mCRPC, isatuximab monotherapy

    Participants with mCRPC will be given isatuximab dose 2

    Drug: Isatuximab SAR650984
    Pharmaceutical form: solution for infusion Route of administration: intravenous
    Other Names:
  • Sarclisa
  • Experimental: Phase 2 Cohort B: NSCLC

    Participants with NSCLC will be given isatuximab dose determined in Phase 1 arm of study and REGN2810 predefined dose

    Drug: Isatuximab SAR650984
    Pharmaceutical form: solution for infusion Route of administration: intravenous
    Other Names:
  • Sarclisa
  • Drug: Cemiplimab REGN2810
    Pharmaceutical form: solution for infusion Route of administration: intravenous

    Experimental: Possibly Phase 2 Cohort C: mCRPC

    Isatuximab dose 3 will be given in combination with REGN2810 predefined dose or isatuximab dose 3 will be given as monotherapy in participants with mCRPC

    Drug: Isatuximab SAR650984
    Pharmaceutical form: solution for infusion Route of administration: intravenous
    Other Names:
  • Sarclisa
  • Drug: Cemiplimab REGN2810
    Pharmaceutical form: solution for infusion Route of administration: intravenous

    Experimental: Possibly Phase 2 Cohort D: NSCLC

    Isatuximab dose 3 will be given in combination with REGN2810 predefined dose

    Drug: Isatuximab SAR650984
    Pharmaceutical form: solution for infusion Route of administration: intravenous
    Other Names:
  • Sarclisa
  • Drug: Cemiplimab REGN2810
    Pharmaceutical form: solution for infusion Route of administration: intravenous

    Outcome Measures

    Primary Outcome Measures

    1. Number of Participants With Dose Limiting Toxicities (DLTs) [Cycle 1 (21 days)]

      DLTs: adverse events occurring during 1st treatment cycle, unless due to disease progression/to cause obviously unrelated to investigational medicinal product (IMP) which included:hematological abnormalities: Grade(G) 4 neutropenia(N) for 7/more consecutive days, G3 to G4 N with fever (temperature greater than or equal to [>=] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 to G4 thrombocytopenia with clinically significant bleeding. Non-hematological abnormalities: G4 non-hematologic AE, G>=2 uveitis, G3 non-hematological AE lasting greater than (>)3 days (except G3 fatigue, allergic reaction/hypersensitivity attributed to isatuximab or REGN2810 and G3 or G4 clinically non-significant laboratory abnormality), delay in initiation of Cycle 2 >14 days due to treatment related laboratory abnormalities/AE. Any other toxicity that Investigator and Sponsor deemed to be dose-limiting, regardless of grade, was also considered as DLT.

    2. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) [From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)]

      An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study treatment up to 30 days after the last dose of study treatment). TEAEs included both SAEs and non-SAEs.

    3. Number of Participants With Laboratory Abnormalities: Hematological Parameters [From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)]

      Hematological parameters assessed were anemia, white blood cell (WBC) decreased, platelet count decreased, lymphocyte count decreased and neutrophil count decreased. Abnormality criteria was based on National Cancer Institute Common Terminology Criteria for Adverse Event version 4.03 (NCI-CTCAE v 4.03), where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.

    4. Number of Participants With Laboratory Abnormalities: Electrolytes [From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)]

      Abnormal electrolytes parameters assessed were hyponatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypoalbuminemia and hyperglycemia. Abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.

    5. Number of Participants With Laboratory Abnormalities: Renal Parameters [From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)]

      Abnormal renal parameters assessed were creatinine clearance (CrCl), creatinine increased and hyperuricemia. Creatinine clearance was assessed in categories: >=60 - less than (<) 90 milliliters per minute per 1.73 square meter (mL/min/1.73m^2), >=30 - <60 mL/min/1.73m^2, >=15 - <30 mL/min/1.73m^2 and <15 mL/min/1.73m^2. Creatinine increased and hyperuricemia abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. For all these 3 parameters, only those categories in which at least 1 participant had data were reported.

    6. Number of Participants With Laboratory Abnormalities: Liver Function Parameters [From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)]

      Abnormal liver function parameters assessed were aspartate aminotransferase (AST) increased, alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, blood bilirubin (BB) increased. Abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.

    7. Overall Response Rate (ORR): Percentage of Participants With Overall Response [From the date of randomization to the date of first documentation of progression or death due to any cause, whichever occurred first (maximum duration: up to 2 years)]

      For participants with mCRPC, response was defined as achieving complete response (CR) or partial response (PR) as best overall response (BOR) for soft tissue assessed and confirmed by the Investigators and/or a prostate-specific antigen (PSA) decline of >=50 percent (%) from Baseline that was subsequently confirmed per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria. For participants with NSCLC, ORR was defined as the percentage of participants with CR or PR as BOR according to RECIST 1.1. criteria. Per RECIST 1.1. criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to <10 millimeters (mm) and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters.

    Secondary Outcome Measures

    1. Number of Participants With Anti-drug Antibodies (ADA) Response Against Isatuximab, Post Treatment [From Baseline up to 2 years]

      ADA response were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).

    2. Number of Participants With Anti-drug Antibodies (ADA) Response Against REGN2810, Post Treatment [From Baseline up to 2 years]

      ADA response were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).

    3. Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of Isatuximab [At start of infusion (SOI), before actual end of infusion (EOI), EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1]

      Cmax was defined as the maximum observed plasma concentration. Cmax analysis was done separately for isatuximab for participants with mCRPC and NSCLC.

    4. Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of REGN2810 [At SOI, before actual EOI, EOI+4 hours, 72 hours, 168 hours, and 336 hours post-dose on Day 1 of Cycle 1]

      Cmax was defined as the maximum observed plasma concentration. Cmax analysis was done separately for REGN2810 for participants with mCRPC and NSCLC.

    5. Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours (AUC0-168 hr) After the First Administration of Isatuximab [At SOI, before actual EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1]

      AUC0-168 hr was defined as the area under the plasma concentration-time curve from time zero to 168h and was calculated using the trapezoidal method over the dosing interval (i.e., 7 days) for isatuximab alone.

    6. Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 504 Hours (AUC0-504 hr) After the First Administration of REGN2810 [At SOI, before actual EOI, EOI+4 hours, 72 hours, 168 hours, 336 hours and 504 hours post-dose on Day 1 of Cycle 1]

      AUC0-504 hr was defined as the area under the plasma concentration-time curve from time zero to 504h and was calculated using the trapezoidal method over the dosing interval (i.e., 21 days) for REGN2810 alone.

    7. Best Percent-change From Baseline in Tumor Burden [Up to 2 years]

      Tumor burden change was defined as the best percent-change from Baseline in a sum of the diameters (longest for non-nodal lesion, short axis for nodal lesions) for all target lesions.

    8. Duration of Response (DOR) [From the date of first response until disease progression or death, whichever occurred first (maximum duration: up to 2 years)]

      DOR: defined as time (in months) from date of first response (PR or CR in radiographic objective response, or PSA decline >=50% for participants with mCRPC) that was subsequently confirmed to the date of first disease progression (PD) or death, whichever occurred first. PD included radiographic disease progression or unequivocal clinical progression. RECIST 1.1 criteria was used to assess radiographic PD in participants with NSCLC and PCWG3 criteria for participants with mCRPC. Per RECIST 1.1 criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target/non-target) must had reduction in short axis to <10 mm and PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (Baseline sum if that was smallest), sum with an absolute increase of at least 5 mm and appearance of 1 or more new lesions.

    9. Progression-free Survival (PFS) [From the date of the first study treatment administration to the date of first documented disease progression or death of any cause, whichever occurred first (maximum duration: up to 2 years)]

      For mCRPC participants, PFS was defined as the time (in months) from first study treatment administration to the date of first documented disease progression or the date of death from any cause, whichever occurred first. Disease progression included radiographic disease progression (per PCWG3 criteria) or unequivocal clinical progression. For NSCLC participants, PFS was defined as the time from first study treatment administration to the date of first documented radiographic progression (PD) (per RECIST 1.1) or the date of death from any cause, whichever occurred first. Per RECIST 1.1 criteria, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the Baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm. Appearance of 1 or more new lesions was also considered as progression. Analysis was performed using Kaplan-Meier method.

    10. Percentage of Participants With Disease Control (DC) >=6 Months [From the date of first response to the date of first documented disease progression or death (due to any cause) (maximum duration: up to 2 years)]

      Disease control: defined as percentage of participants with confirmed CR/PR/stable disease (SD), as assessed by Investigator PCWG3 modified RECIST 1.1 criteria relative to total number of participants in analysis population. Per PCWG3 modified RECIST 1.1 criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target/non-target) must had reduction in short axis to <10 mm, PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference Baseline sum diameters and SD: neither sufficient shrinkage from the Baseline to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum diameters while on study. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study, sum with an absolute increase of diameter of at least 5 mm and appearance of 1 or more new lesions.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Participants must had a known diagnosis of either metastatic castration-resistant prostate cancer (mCRPC) or non-small cell lung cancer (NSCLC) with evidence of measurable disease.

    • Failure of, inability to, or refusal to receive standard of care.

    • Greater than or equal to (>=) 18 years of age.

    Exclusion Criteria:
    • Prior exposure to isatuximab or participation in clinical studies with isatuximab.

    • For participants with mCRPC, prior exposure to any agent (approved or investigational) that blocks the PD-1/PD-L1 pathway.

    • Evidence of other immune related disease /conditions.

    • History of non-infectious pneumonitis requiring steroids or current pneumonitis; history of the thoracic radiation.

    • Had received a live-virus vaccination within 28 days of planned treatment start. Seasonal flu vaccines that do not contain live virus were permitted.

    • Prior solid organ or hematologic transplant.

    • Eastern Cooperative Oncology Group performance status (PS) >=2.

    • Poor bone marrow reserve.

    • Poor organ function.

    The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Investigational Site Number 8400003 Birmingham Alabama United States 35249
    2 Investigational Site Number 8400007 Atlanta Georgia United States 30322
    3 Investigational Site Number 8400002 Hackensack New Jersey United States 07601
    4 Investigational Site Number 8400005 Nashville Tennessee United States 37203
    5 Investigational Site Number 8400004 Houston Texas United States 77030
    6 Investigational Site Number 2500002 Bordeaux Cedex France 33076
    7 Investigational Site Number 2500001 Villejuif France 94800
    8 Investigational Site Number 3800003 Rozzano Milano Italy 20089
    9 Investigational Site Number 3800001 Orbassano Torino Italy 10043
    10 Investigational Site Number 3800006 Napoli Italy 80131
    11 Investigational Site Number 3800004 Padova Italy 35128
    12 Investigational Site Number 3800005 Verona Italy 37134
    13 Investigational Site Number 1580002 Tainan Taiwan 704
    14 Investigational Site Number 1580001 Taipei 100 Taiwan
    15 Investigational Site Number 8260001 Sutton Surrey United Kingdom SM2 5PT
    16 Investigational Site Number 8260002 Newcastle upon Tyne United Kingdom NE7 7DN

    Sponsors and Collaborators

    • Sanofi

    Investigators

    • Study Director: Clinical Sciences & Operations, Sanofi

    Study Documents (Full-Text)

    More Information

    Publications

    None provided.
    Responsible Party:
    Sanofi
    ClinicalTrials.gov Identifier:
    NCT03367819
    Other Study ID Numbers:
    • ACT15319
    • 2017-002846-61
    • U1111-1197-7792
    First Posted:
    Dec 11, 2017
    Last Update Posted:
    May 16, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Sanofi
    Additional relevant MeSH terms:

    Study Results

    Participant Flow

    Recruitment Details Study was conducted at 16 active sites in 5 countries. A total of 44 participants were enrolled between 04 January 2018 and 18 January 2019 and received isatuximab in combination with REGN2810.
    Pre-assignment Detail The study was planned to be conducted in 3 parts: Phase 1 part (safety run-in), Phase 2 part (efficacy) and Cross-over part (a subpart of Cohort A-2). Since the enrolled participants (24 for metastatic, castration-resistant prostate cancer [mCRPC] Cohort A-1 and 20 participants for non-small cell lung cancer [NSCLC] Cohort B) did not achieve the pre-defined efficacy criteria, the study was stopped per-protocol and thus, few planned outcome measures were not analyzed.
    Arm/Group Title mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Arm/Group Description Participants with mCRPC received intravenous (IV) infusion of isatuximab 10 milligrams per kilogram (mg/kg) once weekly (QW) for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    Period Title: Overall Study
    STARTED 24 20
    COMPLETED 0 1
    NOT COMPLETED 24 19

    Baseline Characteristics

    Arm/Group Title mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810 Total Title
    Arm/Group Description Participants with mCRPC received intravenous (IV) infusion of isatuximab 10 milligrams per kilogram (mg/kg) once weekly (QW) for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    Overall Participants 24 20 44
    Age (years) [Mean (Standard Deviation) ]
    Mean (Standard Deviation) [years]
    70.7
    (6.5)
    65.4
    (5.8)
    68.3
    (6.7)
    Sex: Female, Male (Count of Participants)
    Female
    0
    0%
    6
    30%
    6
    13.6%
    Male
    24
    100%
    14
    70%
    38
    86.4%
    Race (NIH/OMB) (Count of Participants)
    American Indian or Alaska Native
    0
    0%
    0
    0%
    0
    0%
    Asian
    6
    25%
    5
    25%
    11
    25%
    Native Hawaiian or Other Pacific Islander
    0
    0%
    0
    0%
    0
    0%
    Black or African American
    0
    0%
    1
    5%
    1
    2.3%
    White
    18
    75%
    10
    50%
    28
    63.6%
    More than one race
    0
    0%
    0
    0%
    0
    0%
    Unknown or Not Reported
    0
    0%
    4
    20%
    4
    9.1%

    Outcome Measures

    1. Primary Outcome
    Title Number of Participants With Dose Limiting Toxicities (DLTs)
    Description DLTs: adverse events occurring during 1st treatment cycle, unless due to disease progression/to cause obviously unrelated to investigational medicinal product (IMP) which included:hematological abnormalities: Grade(G) 4 neutropenia(N) for 7/more consecutive days, G3 to G4 N with fever (temperature greater than or equal to [>=] 38.5 degree Celsius on more than 1 occasion) or microbiologically/radiographically documented infection, G3 to G4 thrombocytopenia with clinically significant bleeding. Non-hematological abnormalities: G4 non-hematologic AE, G>=2 uveitis, G3 non-hematological AE lasting greater than (>)3 days (except G3 fatigue, allergic reaction/hypersensitivity attributed to isatuximab or REGN2810 and G3 or G4 clinically non-significant laboratory abnormality), delay in initiation of Cycle 2 >14 days due to treatment related laboratory abnormalities/AE. Any other toxicity that Investigator and Sponsor deemed to be dose-limiting, regardless of grade, was also considered as DLT.
    Time Frame Cycle 1 (21 days)

    Outcome Measure Data

    Analysis Population Description
    Analysis was performed on DLT evaluable population which included participants who received the planned doses of isatuximab and REGN2810 during Cycle 1, and who completed the DLT observation period after the first IMP administration, unless they discontinued the study treatment(s) due to DLT.
    Arm/Group Title mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Arm/Group Description Participants with mCRPC received intravenous (IV) infusion of isatuximab 10 milligrams per kilogram (mg/kg) once weekly (QW) for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    Measure Participants 5 1
    Count of Participants [Participants]
    0
    0%
    0
    0%
    2. Primary Outcome
    Title Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
    Description An AE was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the TEAE period (defined as the time from the first dose of study treatment up to 30 days after the last dose of study treatment). TEAEs included both SAEs and non-SAEs.
    Time Frame From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)

    Outcome Measure Data

    Analysis Population Description
    Analysis was performed on all-treated population.
    Arm/Group Title mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Arm/Group Description Participants with mCRPC received intravenous (IV) infusion of isatuximab 10 milligrams per kilogram (mg/kg) once weekly (QW) for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    Measure Participants 24 20
    Any TEAEs
    24
    100%
    20
    100%
    Any TESAEs
    11
    45.8%
    14
    70%
    3. Primary Outcome
    Title Number of Participants With Laboratory Abnormalities: Hematological Parameters
    Description Hematological parameters assessed were anemia, white blood cell (WBC) decreased, platelet count decreased, lymphocyte count decreased and neutrophil count decreased. Abnormality criteria was based on National Cancer Institute Common Terminology Criteria for Adverse Event version 4.03 (NCI-CTCAE v 4.03), where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.
    Time Frame From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)

    Outcome Measure Data

    Analysis Population Description
    Analysis was performed on all-treated population. Here, overall number of participants analyzed = participants evaluable for this outcome measure.
    Arm/Group Title mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Arm/Group Description Participants with mCRPC received intravenous (IV) infusion of isatuximab 10 milligrams per kilogram (mg/kg) once weekly (QW) for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    Measure Participants 23 20
    Anemia: Grade 1
    10
    41.7%
    9
    45%
    Anemia: Grade 2
    9
    37.5%
    2
    10%
    Anemia: Grade 3
    4
    16.7%
    3
    15%
    WBC decreased: Grade 1
    8
    33.3%
    2
    10%
    WBC decreased: Grade 2
    5
    20.8%
    0
    0%
    Platelet count decreased: Grade 1
    5
    20.8%
    1
    5%
    Platelet count decreased: Grade 2
    2
    8.3%
    0
    0%
    Platelet count decreased: Grade 3
    1
    4.2%
    0
    0%
    Lymphocyte count decreased: Grade 1
    4
    16.7%
    7
    35%
    Lymphocyte count decreased: Grade 2
    8
    33.3%
    4
    20%
    Lymphocyte count decreased: Grade 3
    5
    20.8%
    2
    10%
    Lymphocyte count decreased: Grade 4
    1
    4.2%
    0
    0%
    Neutrophil count decreased: Grade 1
    3
    12.5%
    2
    10%
    Neutrophil count decreased: Grade 2
    2
    8.3%
    0
    0%
    4. Primary Outcome
    Title Number of Participants With Laboratory Abnormalities: Electrolytes
    Description Abnormal electrolytes parameters assessed were hyponatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypoalbuminemia and hyperglycemia. Abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.
    Time Frame From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)

    Outcome Measure Data

    Analysis Population Description
    Analysis was performed on all-treated population. Here, overall number of participants analyzed = participants evaluable for this outcome measure.
    Arm/Group Title mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Arm/Group Description Participants with mCRPC received intravenous (IV) infusion of isatuximab 10 milligrams per kilogram (mg/kg) once weekly (QW) for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    Measure Participants 23 20
    Hyponatremia: Grade 1
    8
    33.3%
    8
    40%
    Hypokalemia: Grade 1
    3
    12.5%
    2
    10%
    Hyperkalemia: Grade 1
    3
    12.5%
    2
    10%
    Hypocalcemia: Grade 1
    6
    25%
    3
    15%
    Hypocalcemia: Grade 2
    1
    4.2%
    0
    0%
    Hypercalcemia: Grade 1
    1
    4.2%
    1
    5%
    Hypercalcemia: Grade 2
    0
    0%
    1
    5%
    Hypoalbuminemia: Grade 1
    6
    25%
    2
    10%
    Hypoalbuminemia: Grade 2
    1
    4.2%
    3
    15%
    Hypoalbuminemia: Grade 3
    0
    0%
    1
    5%
    Hyperglycemia: Grade 1
    11
    45.8%
    3
    15%
    Hyperglycemia: Grade 2
    5
    20.8%
    5
    25%
    Hyperglycemia: Grade 3
    1
    4.2%
    0
    0%
    Hypoglycemia: Grade 1
    0
    0%
    1
    5%
    Hypoglycemia: Grade 2
    0
    0%
    1
    5%
    5. Primary Outcome
    Title Number of Participants With Laboratory Abnormalities: Renal Parameters
    Description Abnormal renal parameters assessed were creatinine clearance (CrCl), creatinine increased and hyperuricemia. Creatinine clearance was assessed in categories: >=60 - less than (<) 90 milliliters per minute per 1.73 square meter (mL/min/1.73m^2), >=30 - <60 mL/min/1.73m^2, >=15 - <30 mL/min/1.73m^2 and <15 mL/min/1.73m^2. Creatinine increased and hyperuricemia abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. For all these 3 parameters, only those categories in which at least 1 participant had data were reported.
    Time Frame From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)

    Outcome Measure Data

    Analysis Population Description
    Analysis was performed on all-treated population. Here, overall number of participants analyzed = participants evaluable for this outcome measure.
    Arm/Group Title mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Arm/Group Description Participants with mCRPC received intravenous (IV) infusion of isatuximab 10 milligrams per kilogram (mg/kg) once weekly (QW) for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    Measure Participants 23 20
    CrCl: >=60 - <90 mL/min/1.73m^2
    6
    25%
    13
    65%
    CrCl: >=30 - <60 mL/min/1.73m^2
    11
    45.8%
    2
    10%
    Creatinine increased: Grade 1
    18
    75%
    15
    75%
    Hyperuricemia: Grade 3
    2
    8.3%
    3
    15%
    Hyperuricemia: Grade 4
    1
    4.2%
    0
    0%
    6. Primary Outcome
    Title Number of Participants With Laboratory Abnormalities: Liver Function Parameters
    Description Abnormal liver function parameters assessed were aspartate aminotransferase (AST) increased, alanine aminotransferase (ALT) increased, alkaline phosphatase (ALP) increased, blood bilirubin (BB) increased. Abnormality criteria was based on NCI-CTCAE v 4.03, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Only those categories in which at least 1 participant had data were reported.
    Time Frame From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)

    Outcome Measure Data

    Analysis Population Description
    Analysis was performed on all-treated population. Here, overall number of participants analyzed = participants evaluable for this outcome measure.
    Arm/Group Title mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Arm/Group Description Participants with mCRPC received intravenous (IV) infusion of isatuximab 10 milligrams per kilogram (mg/kg) once weekly (QW) for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    Measure Participants 23 20
    AST increased: Grade 1
    6
    25%
    2
    10%
    AST increased: Grade 2
    1
    4.2%
    0
    0%
    ALT increased: Grade 1
    2
    8.3%
    0
    0%
    ALP increased: Grade 1
    3
    12.5%
    9
    45%
    ALP increased: Grade 2
    4
    16.7%
    0
    0%
    ALP increased: Grade 3
    6
    25%
    0
    0%
    BB increased: Grade 1
    2
    8.3%
    1
    5%
    7. Primary Outcome
    Title Overall Response Rate (ORR): Percentage of Participants With Overall Response
    Description For participants with mCRPC, response was defined as achieving complete response (CR) or partial response (PR) as best overall response (BOR) for soft tissue assessed and confirmed by the Investigators and/or a prostate-specific antigen (PSA) decline of >=50 percent (%) from Baseline that was subsequently confirmed per Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria. For participants with NSCLC, ORR was defined as the percentage of participants with CR or PR as BOR according to RECIST 1.1. criteria. Per RECIST 1.1. criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to <10 millimeters (mm) and PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters.
    Time Frame From the date of randomization to the date of first documentation of progression or death due to any cause, whichever occurred first (maximum duration: up to 2 years)

    Outcome Measure Data

    Analysis Population Description
    Analysis was performed on all-treated population.
    Arm/Group Title mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Arm/Group Description Participants with mCRPC received intravenous (IV) infusion of isatuximab 10 milligrams per kilogram (mg/kg) once weekly (QW) for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    Measure Participants 24 20
    Number (90% Confidence Interval) [percentage of participants]
    4.2
    17.5%
    0
    0%
    8. Secondary Outcome
    Title Number of Participants With Anti-drug Antibodies (ADA) Response Against Isatuximab, Post Treatment
    Description ADA response were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).
    Time Frame From Baseline up to 2 years

    Outcome Measure Data

    Analysis Population Description
    Analyzed on ADA population: all participants who signed the study IC and received at least 1 dose (even incomplete) of the study treatments, either isatuximab or REGN2810 and had at least 1 ADA non-missing results after the first dose of study treatment. Here, 'overall number of participants analyzed'= participants evaluable for this outcome measure. For this outcome measure, combined ADA analysis was planned and performed for participants with mCRPC and NSCLC.
    Arm/Group Title mCRPC + NSCLC : Isatuximab + REGN2810
    Arm/Group Description Participants with mCRPC and NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15 of Cycle 1) and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    Measure Participants 39
    Count of Participants [Participants]
    0
    0%
    9. Secondary Outcome
    Title Number of Participants With Anti-drug Antibodies (ADA) Response Against REGN2810, Post Treatment
    Description ADA response were categorized as treatment boosted ADA and treatment-induced ADA. Treatment boosted ADA was defined as pre-existing ADAs with a significant increase in the ADA titer during the study compared to the Baseline titer. Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA (including participants without pretreatment samples).
    Time Frame From Baseline up to 2 years

    Outcome Measure Data

    Analysis Population Description
    Analysis was performed on ADA population. Here, 'overall number of participants analyzed' = participants evaluable for this outcome measure. For this outcome measure, combined ADA analysis was planned and performed for participants with mCRPC and NSCLC.
    Arm/Group Title mCRPC + NSCLC : Isatuximab + REGN2810
    Arm/Group Description Participants with mCRPC and NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15 of Cycle 1) and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    Measure Participants 39
    Count of Participants [Participants]
    1
    4.2%
    10. Secondary Outcome
    Title Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of Isatuximab
    Description Cmax was defined as the maximum observed plasma concentration. Cmax analysis was done separately for isatuximab for participants with mCRPC and NSCLC.
    Time Frame At start of infusion (SOI), before actual end of infusion (EOI), EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1

    Outcome Measure Data

    Analysis Population Description
    Analyzed on PK population which included all participants who signed the study IC and received at least 1 dose (even incomplete) of the study treatments, either isatuximab or REGN2810 and had at least 1 drug concentration after the first dose of study treatment. Here, overall number of participants analyzed = participants with available data for this outcome measure.
    Arm/Group Title mCRPC: Isatuximab NSCLC: Isatuximab
    Arm/Group Description Participants with mCRPC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15 of Cycle 1) and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days) (Maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15 of Cycle 1) and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days)) (Maximum duration: up to 2 years).
    Measure Participants 17 16
    Mean (Standard Deviation) [micrograms per milliliter]
    291
    (67.9)
    280
    (54.5)
    11. Secondary Outcome
    Title Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) After the First Infusion of REGN2810
    Description Cmax was defined as the maximum observed plasma concentration. Cmax analysis was done separately for REGN2810 for participants with mCRPC and NSCLC.
    Time Frame At SOI, before actual EOI, EOI+4 hours, 72 hours, 168 hours, and 336 hours post-dose on Day 1 of Cycle 1

    Outcome Measure Data

    Analysis Population Description
    Analysis was performed on PK population. Here, overall number of participants analyzed = participants with available data for this outcome measure.
    Arm/Group Title mCRPC: REGN2810 NSCLC: REGN2810
    Arm/Group Description Participants with mCRPC received IV infusion of REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (Maximum duration: up to 2 years). Participants with NSCLC received IV infusion of REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (Maximum duration: up to 2 years).
    Measure Participants 19 17
    Mean (Standard Deviation) [milligrams per liter]
    102
    (26.1)
    116
    (21.4)
    12. Secondary Outcome
    Title Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 168 Hours (AUC0-168 hr) After the First Administration of Isatuximab
    Description AUC0-168 hr was defined as the area under the plasma concentration-time curve from time zero to 168h and was calculated using the trapezoidal method over the dosing interval (i.e., 7 days) for isatuximab alone.
    Time Frame At SOI, before actual EOI, EOI+4 hours, 72 hours and 168 hours post-dose on Day 1 of Cycle 1

    Outcome Measure Data

    Analysis Population Description
    Analysis was performed on PK population. Here, overall number of participants analyzed = participants with available data for this outcome measure.
    Arm/Group Title mCRPC: Isatuximab NSCLC: Isatuximab
    Arm/Group Description Participants with mCRPC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15 of Cycle 1) and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days) (Maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15 of Cycle 1) and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days)) (Maximum duration: up to 2 years).
    Measure Participants 16 14
    Mean (Standard Deviation) [micrograms*hour per milliliter]
    28400
    (6610)
    24500
    (5510)
    13. Secondary Outcome
    Title Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to 504 Hours (AUC0-504 hr) After the First Administration of REGN2810
    Description AUC0-504 hr was defined as the area under the plasma concentration-time curve from time zero to 504h and was calculated using the trapezoidal method over the dosing interval (i.e., 21 days) for REGN2810 alone.
    Time Frame At SOI, before actual EOI, EOI+4 hours, 72 hours, 168 hours, 336 hours and 504 hours post-dose on Day 1 of Cycle 1

    Outcome Measure Data

    Analysis Population Description
    Analysis was performed on PK population. Here, overall number of participants analyzed = participants with available data for this outcome measure.
    Arm/Group Title mCRPC: REGN2810 NSCLC: REGN2810
    Arm/Group Description Participants with mCRPC received IV infusion of REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (Maximum duration: up to 2 years). Participants with NSCLC received IV infusion of REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (Maximum duration: up to 2 years).
    Measure Participants 19 7
    Mean (Standard Deviation) [milligrams*day per liter]
    903
    (257)
    1020
    (229)
    14. Secondary Outcome
    Title Best Percent-change From Baseline in Tumor Burden
    Description Tumor burden change was defined as the best percent-change from Baseline in a sum of the diameters (longest for non-nodal lesion, short axis for nodal lesions) for all target lesions.
    Time Frame Up to 2 years

    Outcome Measure Data

    Analysis Population Description
    Analysis was performed on all-treated population.
    Arm/Group Title mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Arm/Group Description Participants with mCRPC received intravenous (IV) infusion of isatuximab 10 milligrams per kilogram (mg/kg) once weekly (QW) for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    Measure Participants 24 20
    Mean (Standard Deviation) [percent change]
    12.9
    (47.6)
    0.7
    (10.1)
    15. Secondary Outcome
    Title Duration of Response (DOR)
    Description DOR: defined as time (in months) from date of first response (PR or CR in radiographic objective response, or PSA decline >=50% for participants with mCRPC) that was subsequently confirmed to the date of first disease progression (PD) or death, whichever occurred first. PD included radiographic disease progression or unequivocal clinical progression. RECIST 1.1 criteria was used to assess radiographic PD in participants with NSCLC and PCWG3 criteria for participants with mCRPC. Per RECIST 1.1 criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target/non-target) must had reduction in short axis to <10 mm and PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference baseline sum diameters. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study (Baseline sum if that was smallest), sum with an absolute increase of at least 5 mm and appearance of 1 or more new lesions.
    Time Frame From the date of first response until disease progression or death, whichever occurred first (maximum duration: up to 2 years)

    Outcome Measure Data

    Analysis Population Description
    Analysis was performed on subset of participants who had response. Here, '0' in 'overall number of participants analyzed represents that DOR could only be analyzed in participants who achieved a response. As no participant in the NSCLC cohort achieved any response, no DOR is available.
    Arm/Group Title mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Arm/Group Description Participants with mCRPC received intravenous (IV) infusion of isatuximab 10 milligrams per kilogram (mg/kg) once weekly (QW) for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    Measure Participants 1 0
    Mean (Standard Deviation) [months]
    4.17
    16. Secondary Outcome
    Title Progression-free Survival (PFS)
    Description For mCRPC participants, PFS was defined as the time (in months) from first study treatment administration to the date of first documented disease progression or the date of death from any cause, whichever occurred first. Disease progression included radiographic disease progression (per PCWG3 criteria) or unequivocal clinical progression. For NSCLC participants, PFS was defined as the time from first study treatment administration to the date of first documented radiographic progression (PD) (per RECIST 1.1) or the date of death from any cause, whichever occurred first. Per RECIST 1.1 criteria, PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the Baseline sum if that is the smallest on study). The sum must also demonstrate an absolute increase of at least 5 mm. Appearance of 1 or more new lesions was also considered as progression. Analysis was performed using Kaplan-Meier method.
    Time Frame From the date of the first study treatment administration to the date of first documented disease progression or death of any cause, whichever occurred first (maximum duration: up to 2 years)

    Outcome Measure Data

    Analysis Population Description
    Analysis was performed on all-treated population.
    Arm/Group Title mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Arm/Group Description Participants with mCRPC received intravenous (IV) infusion of isatuximab 10 milligrams per kilogram (mg/kg) once weekly (QW) for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    Measure Participants 24 20
    Median (95% Confidence Interval) [months]
    2.30
    4.01
    17. Secondary Outcome
    Title Percentage of Participants With Disease Control (DC) >=6 Months
    Description Disease control: defined as percentage of participants with confirmed CR/PR/stable disease (SD), as assessed by Investigator PCWG3 modified RECIST 1.1 criteria relative to total number of participants in analysis population. Per PCWG3 modified RECIST 1.1 criteria, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target/non-target) must had reduction in short axis to <10 mm, PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference Baseline sum diameters and SD: neither sufficient shrinkage from the Baseline to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum diameters while on study. PD: at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum on study, sum with an absolute increase of diameter of at least 5 mm and appearance of 1 or more new lesions.
    Time Frame From the date of first response to the date of first documented disease progression or death (due to any cause) (maximum duration: up to 2 years)

    Outcome Measure Data

    Analysis Population Description
    Analysis was performed on all-treated population. Here, '0' in 'overall number of participants analyzed represents that data for this outcome measure was not analyzed for NSCLC arm because there was insufficient data to perform the DC analysis.
    Arm/Group Title mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Arm/Group Description Participants with mCRPC received intravenous (IV) infusion of isatuximab 10 milligrams per kilogram (mg/kg) once weekly (QW) for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    Measure Participants 24 0
    Number (90% Confidence Interval) [percentage of participants]
    20.8
    86.7%

    Adverse Events

    Time Frame From Baseline up to 30 days after the last dose of study treatments (maximum duration: up to 2 years)
    Adverse Event Reporting Description Reported adverse events (AE) and deaths were TEAEs i.e., AE that developed, worsened, or became serious during the TEAE period (time from the first dose of study treatment up to 30 days after last dose of study treatment). Analysis was performed on all-treated population.
    Arm/Group Title mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Arm/Group Description Participants with mCRPC received intravenous (IV) infusion of isatuximab 10 milligrams per kilogram (mg/kg) once weekly (QW) for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years). Participants with NSCLC received IV infusion of isatuximab 10 mg/kg QW for 3 weeks (i.e., on Days 1, 8 and 15) of Cycle 1 and then on Day 1 of Cycle 2 and subsequent cycles (each cycle of 21 days), along with REGN2810 350 mg IV infusion on Day 1 of each 21-day treatment Cycle (maximum duration: up to 2 years).
    All Cause Mortality
    mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 2/24 (8.3%) 2/20 (10%)
    Serious Adverse Events
    mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 11/24 (45.8%) 14/20 (70%)
    Cardiac disorders
    Atrial Fibrillation 1/24 (4.2%) 1 0/20 (0%) 0
    Gastrointestinal disorders
    Immune-Mediated Enterocolitis 0/24 (0%) 0 1/20 (5%) 1
    Intestinal Obstruction 0/24 (0%) 0 1/20 (5%) 1
    Malignant Dysphagia 0/24 (0%) 0 1/20 (5%) 1
    General disorders
    Disease Progression 0/24 (0%) 0 1/20 (5%) 1
    Infections and infestations
    Pneumonia 0/24 (0%) 0 2/20 (10%) 2
    Urinary Tract Infection 1/24 (4.2%) 1 0/20 (0%) 0
    Urosepsis 1/24 (4.2%) 1 0/20 (0%) 0
    Injury, poisoning and procedural complications
    Infusion Related Reaction 2/24 (8.3%) 2 1/20 (5%) 1
    Post Procedural Haematoma 0/24 (0%) 0 1/20 (5%) 1
    Musculoskeletal and connective tissue disorders
    Back Pain 1/24 (4.2%) 1 0/20 (0%) 0
    Muscular Weakness 1/24 (4.2%) 1 0/20 (0%) 0
    Spinal Pain 1/24 (4.2%) 1 0/20 (0%) 0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Cancer Pain 0/24 (0%) 0 1/20 (5%) 1
    Malignant Pleural Effusion 1/24 (4.2%) 3 0/20 (0%) 0
    Metastases To Peritoneum 0/24 (0%) 0 1/20 (5%) 1
    Metastases To Spinal Cord 0/24 (0%) 0 1/20 (5%) 1
    Tumour Necrosis 0/24 (0%) 0 1/20 (5%) 1
    Nervous system disorders
    Headache 1/24 (4.2%) 1 0/20 (0%) 0
    Spinal Cord Compression 0/24 (0%) 0 1/20 (5%) 1
    Renal and urinary disorders
    Hydronephrosis 1/24 (4.2%) 1 0/20 (0%) 0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea 0/24 (0%) 0 2/20 (10%) 2
    Immune-Mediated Pneumonitis 1/24 (4.2%) 2 1/20 (5%) 1
    Pulmonary Embolism 0/24 (0%) 0 1/20 (5%) 1
    Respiratory Failure 1/24 (4.2%) 1 0/20 (0%) 0
    Other (Not Including Serious) Adverse Events
    mCRPC: Isatuximab + REGN2810 NSCLC: Isatuximab + REGN2810
    Affected / at Risk (%) # Events Affected / at Risk (%) # Events
    Total 24/24 (100%) 19/20 (95%)
    Gastrointestinal disorders
    Abdominal Pain 2/24 (8.3%) 2 2/20 (10%) 2
    Abdominal Pain Upper 1/24 (4.2%) 1 3/20 (15%) 3
    Constipation 2/24 (8.3%) 2 2/20 (10%) 2
    Diarrhoea 5/24 (20.8%) 6 2/20 (10%) 2
    Nausea 4/24 (16.7%) 4 3/20 (15%) 3
    Stomatitis 2/24 (8.3%) 2 0/20 (0%) 0
    Vomiting 3/24 (12.5%) 5 2/20 (10%) 2
    General disorders
    Asthenia 6/24 (25%) 6 4/20 (20%) 4
    Fatigue 8/24 (33.3%) 8 3/20 (15%) 3
    Oedema Peripheral 5/24 (20.8%) 5 0/20 (0%) 0
    Pyrexia 6/24 (25%) 8 4/20 (20%) 4
    Infections and infestations
    Bronchitis 0/24 (0%) 0 2/20 (10%) 2
    Rhinitis 0/24 (0%) 0 2/20 (10%) 2
    Upper Respiratory Tract Infection 3/24 (12.5%) 5 1/20 (5%) 1
    Urinary Tract Infection 2/24 (8.3%) 3 0/20 (0%) 0
    Injury, poisoning and procedural complications
    Infusion Related Reaction 10/24 (41.7%) 10 8/20 (40%) 8
    Metabolism and nutrition disorders
    Decreased Appetite 9/24 (37.5%) 9 1/20 (5%) 1
    Dehydration 2/24 (8.3%) 2 0/20 (0%) 0
    Musculoskeletal and connective tissue disorders
    Back Pain 7/24 (29.2%) 8 1/20 (5%) 2
    Bone Pain 2/24 (8.3%) 2 1/20 (5%) 1
    Myalgia 3/24 (12.5%) 4 0/20 (0%) 0
    Pain In Extremity 3/24 (12.5%) 4 1/20 (5%) 1
    Nervous system disorders
    Dizziness 2/24 (8.3%) 2 2/20 (10%) 3
    Hypoaesthesia 2/24 (8.3%) 2 0/20 (0%) 0
    Paraesthesia 0/24 (0%) 0 2/20 (10%) 3
    Respiratory, thoracic and mediastinal disorders
    Cough 4/24 (16.7%) 4 6/20 (30%) 9
    Dyspnoea 3/24 (12.5%) 3 2/20 (10%) 2
    Haemoptysis 0/24 (0%) 0 2/20 (10%) 3
    Rhinorrhoea 0/24 (0%) 0 3/20 (15%) 4
    Skin and subcutaneous tissue disorders
    Dry Skin 0/24 (0%) 0 2/20 (10%) 2
    Pruritus 4/24 (16.7%) 5 3/20 (15%) 3
    Vascular disorders
    Deep Vein Thrombosis 2/24 (8.3%) 2 0/20 (0%) 0
    Hypertension 3/24 (12.5%) 4 1/20 (5%) 1
    Hypotension 2/24 (8.3%) 2 2/20 (10%) 2

    Limitations/Caveats

    The study was terminated after the interim analysis of the primary endpoint. Few planned outcome measures per-protocol were not analyzed because overall efficacy results were not sufficient at the time of interim analyses of both the cohorts.

    More Information

    Certain Agreements

    Principal Investigators are NOT employed by the organization sponsoring the study.

    The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.

    Results Point of Contact

    Name/Title Trial Transparency Team
    Organization Sanofi aventis recherche & développement
    Phone 800-633-1610 ext 6#
    Email Contact-US@sanofi.com
    Responsible Party:
    Sanofi
    ClinicalTrials.gov Identifier:
    NCT03367819
    Other Study ID Numbers:
    • ACT15319
    • 2017-002846-61
    • U1111-1197-7792
    First Posted:
    Dec 11, 2017
    Last Update Posted:
    May 16, 2022
    Last Verified:
    Apr 1, 2022